Ashwagandha: The Most Overhyped Supplement of 2026?

← Back to articles

Ashwagandha (Withania somnifera) has become the wellness industry's favorite adaptogen — a category-defining supplement that promises to reduce cortisol, combat stress, improve sleep, boost testosterone, enhance cognitive performance, increase endurance, and support thyroid function, all in one capsule. Google Trends shows a nearly tenfold increase in searches since 2019. It is now the fifth most commonly used natural product in the United States according to NIH survey data.

The honest assessment is more complicated than either the enthusiasts or the skeptics suggest. Ashwagandha has real clinical evidence behind specific effects at specific doses in specific populations. It also has a rapidly expanding list of claims that significantly outpace that evidence. Understanding which is which requires separating the extract quality question, the mechanism question, and the outcome question.

What Ashwagandha Actually Is

Ashwagandha is a root from the nightshade family (Solanaceae) used for over 3,000 years in Ayurvedic medicine. The primary active compounds are withanolides, a class of steroidal lactones that appear to modulate stress response pathways. The root also contains alkaloids, saponins, and iron. The term "adaptogen" has no regulatory or scientific definition — it is a marketing category meant to suggest the plant "helps the body adapt to stress," a claim vague enough to cover almost any effect.

Critically, ashwagandha is not a single standardized compound — it is a complex botanical extract with significant variation between products. The KSM-66 and Sensoril branded extracts used in most clinical trials are standardized to specific withanolide percentages (5% for KSM-66, 10% for Sensoril). Generic ashwagandha powders have wildly variable withanolide content. This means the clinical trial data on KSM-66 and Sensoril cannot be assumed to apply to unlabeled, unstandardized products at GNC, Amazon, or your local health food store.

The Strongest Evidence: Stress and Cortisol

The most replicated finding in ashwagandha clinical trials is a reduction in perceived stress scores and self-reported anxiety, with accompanying reductions in serum cortisol in several studies. A 2012 double-blind, placebo-controlled trial published in the Indian Journal of Psychological Medicine randomized 64 adults with chronic stress to 300 mg of KSM-66 twice daily for 60 days. The ashwagandha group showed a 28% reduction in serum cortisol levels, a 69% reduction in insomnia scores, and statistically significant improvements on every validated stress and anxiety scale used (PSS, GHQ-28, DASS).

These results have been broadly replicated. A 2019 study published in Medicine found that 240 mg/day of a concentrated ashwagandha extract for 60 days significantly reduced anxiety and morning cortisol levels vs. placebo. A 2021 RCT in the Journal of Clinical Medicine found improvements in stress, sleep quality, and overall well-being in 150 mg/day KSM-66 groups over 30 days. The stress/anxiety signal across multiple independent trials from different groups is the most credible finding in the ashwagandha literature.

Sleep: Promising but Modest

Multiple RCTs have tested ashwagandha for sleep. A 2021 meta-analysis in PLOS ONE by Cheah and colleagues pooled five trials and found a statistically significant improvement in overall sleep quality (SMD of about −0.59), with meaningful benefit on sleep efficiency, total sleep time, and sleep latency. The authors described the effects as small to moderate, with a larger benefit in people who had clinical insomnia at baseline. Most of the benefit appears to come through the anxiety-reducing mechanism — by lowering pre-sleep cognitive arousal and cortisol, ashwagandha makes falling asleep easier for people whose insomnia is anxiety-driven.

This is meaningfully different from how the compound is marketed ("deep sleep," "restorative sleep"), which implies a direct pharmacological action on sleep architecture. The evidence suggests it helps mostly by reducing the psychological noise that prevents sleep in stressed individuals, not by acting as a sedative or directly reshaping sleep architecture like melatonin or glycine.

Where the Hype Outpaces the Evidence

Testosterone: Several trials have found modest increases in testosterone (ranging from 10–17% over baseline) in men using ashwagandha, particularly in combination with resistance training. These are statistically significant in small trials but clinically modest — well below the threshold that would produce noticeable anabolic effects. The mechanism is unclear; some researchers propose cortisol reduction secondarily improves testosterone, as the two hormones are metabolically linked. Marketing that frames ashwagandha as a testosterone booster dramatically overstates this finding.

Cognitive function: Several small trials have found improvements in attention, information processing speed, and memory with ashwagandha supplementation. However, most of these trials use populations with baseline cognitive impairment or significant stress loads, and effects in healthy well-rested adults are much less clear. A 2021 RCT in adults without cognitive pathology found no significant cognitive improvement at 300 mg KSM-66 twice daily over 8 weeks.

Athletic performance: A 2015 trial found ashwagandha improved VO2 max and muscle strength/recovery in elite cyclists and elite strength athletes. Other trials in recreational exercisers show more modest effects. The effects appear most pronounced in individuals under high training stress, which again traces back to the cortisol-mediated mechanism rather than direct performance enhancement.

Safety: Mostly Good, With Important Exceptions

Ashwagandha is generally well-tolerated at studied doses. However, a growing number of case reports have linked high-dose ashwagandha to liver injury — autoimmune hepatitis-like presentations requiring hospitalization. As of 2024, ICSR (Individual Case Safety Reports) in the FDA's MedWatch database and published case series had identified approximately 30 suspected cases of ashwagandha-associated hepatotoxicity, with some requiring liver transplant evaluation. The mechanism is poorly understood; it may involve immune-mediated reactions in genetically susceptible individuals rather than direct hepatotoxicity.

These cases are rare relative to the enormous number of people taking ashwagandha globally. But they represent a non-zero risk that has grown as doses have escalated and products have proliferated. Most cases involved doses above 500 mg/day for extended periods, often of products that were not the standardized KSM-66 or Sensoril extracts studied in trials.

Additional cautions: ashwagandha is contraindicated in pregnancy (traditional use as an abortifacient exists in Ayurvedic literature). It should be used cautiously with thyroid medications, as several trials show thyroid-stimulating effects (T3/T4 increases) that could amplify or complicate thyroid drug therapy. The standard recommendation is to cycle use — 8–12 weeks on, 4 weeks off — to avoid chronic exposure.

The Verdict

Ashwagandha is a legitimately effective supplement for stress reduction and anxiety in clinically stressed adults, at 300–600 mg/day of a standardized extract (KSM-66 or Sensoril), for 8–12 week cycles. It is not a testosterone booster, not a universal cognitive enhancer, and not a performance supplement with evidence comparable to creatine. The liver injury signal, while rare, is real and warrants caution at higher doses and in people with pre-existing liver conditions. The gap between what ashwagandha demonstrably does and what the market tells you it does is wide enough to qualify as the most overhyped supplement of the moment — not because the evidence is poor, but because it has been stretched far beyond its actual scope.